New data from Google’s longevity play Calico and the neuro-focused biotech Denali Therapeutics showed neither of their ALS ...
Investor's Business Daily on MSN2h
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.Denali Therapeutics shares slumped for the second straight day Tuesday after the drugmaker's ALS treatment failed in a ...
The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
Denali Therapeutics' DNL343 fails to meet endpoints in the HEALEY ALS study, marking a second clinical setback for the ...
The result is another major disappointment to ALS patients, who have limited drug treatment options at present, particularly ...
Nvidia stock rises after the artificial-intelligence chip maker unveils its next generation gaming graphic cards, while ...
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
The company said Monday that fosigotifator failed to outperform placebo in slowing the neurogenerative disease, but is ...
Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.
Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback